Deepak Hooda, MD
Interventional Cardiology · Wheeling, WVNPI 1033316070
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,262 of the $11,910 with a category attached, or 61.0%. 25 manufacturers reported payments, led by Abbott at 29.8% of the total. Reporting peaked in 2024 at $3,000 and has fallen 71.9% since, to $842 in 2025.
Across 294 payments — averaging $40.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Medtronic$3K
- Edwards Lifesciences$2K
- Boston Scientific$1K
- Abiomed$722
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$429
- plus $1K from 19 others
Across 3 payments — averaging $56.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$170
What the payments were for
- Travel & lodging$4,24836%
- Food & beverage$7,26261%
- Education$4013%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 68 | $3,545 |
| Medtronic(2 entities) | 74 | $2,510 |
| Edwards Lifesciences | 13 | $2,169 |
| Boston Scientific | 55 | $1,386 |
| Abiomed | 11 | $722 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 34 | $429 |
| Impulse Dynamics (USA) Inc. | 1 | $142 |
| Inari Medical, Inc. | 1 | $142 |
| EKOS Corporation | 1 | $134 |
| E.r. Squibb & Sons, L.L.C. | 8 | $127 |
| Shockwave Medical, Inc | 1 | $97 |
| Heartflow, Inc. | 2 | $64 |
| Amgen | 4 | $63 |
| AstraZeneca | 4 | $55 |
| Novartis | 3 | $47 |
| Cerus Corporation | 1 | $47 |
| Cardiovascular Systems Inc. | 2 | $46 |
| Sanofi-aventis U.S. LLC | 3 | $46 |
| Stryker | 1 | $28 |
| Bard Peripheral Vascular, Inc. | 1 | $28 |
| Pfizer | 2 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Cardiva Medical, Inc. | 1 | $15 |
| W. L. Gore & Associates, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$1,457
- Mitra Clip system$1,145
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,044
- AMPLATZER Occluders$646
- Impella$497
- WATCHMAN Access System$145
- AVVIGO Guidance System$144
- OPTIMIZER SMART SYSTEM$142
- FLOWTRIEVER CATHETER, S$142
- CT THROMBECTOMY SYSTEM KIT$142
- EKOSONIC$134
- MitraClip System$122
- AMPLATZER AMULET$121
- IN.PACT Admiral$119
- Watchman$114
How this compares
$11,910 in reported general payments places this provider in the 70th percentile of 46 interventional cardiology providers in West Virginia.
See all interventional cardiology providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 192 | $181,547 |
| EntrestoSacubitril/Valsartan | 66 | $58,338 |
| XareltoRivaroxaban | 47 | $52,397 |
| Repatha SureclickEvolocumab | 36 | $29,912 |
| Metoprolol Succinate | 286 | $3,255 |
| Ranolazine ErRanolazine | 18 | $2,376 |
| Ezetimibe | 71 | $1,214 |
| Rosuvastatin Calcium | 60 | $1,178 |
| Atorvastatin Calcium | 161 | $1,168 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 86 | $1,047 |
| Losartan Potassium | 92 | $974 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 42 | $953 |
| Valsartan | 24 | $779 |
| Potassium Chloride | 35 | $723 |
| Amlodipine Besylate | 138 | $697 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $25 | $181,547192 claims |
| NovartisEntresto | $47 | $58,33866 claims |
| Johnson & JohnsonXarelto | $15 | $52,39747 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 46 interventional cardiology providers in West Virginia.
Other interventional cardiology in Wheeling
- Juan Carlos ArrietaWheeling$7K
- Mark BatesCharleston$288K
- Elie GharibSouth Charleston$240K
- Wissam GharibMorgantown$179K
- Anene UkaigweCharleston$168K
- Aravinda NanjundappaBeckley$166K
- Daniel SnavelyHuntington$120K
- Elise AndersonCharleston$38K
- Richard HanCharleston$38K
- Mehrette MaruHuntington$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.